ACA
ADVM

Avoro Capital Advisors’s Adverum Biotechnologies ADVM Stock Holding History

Avoro Capital Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-416,666
Closed -$2.86M – 37
2024
Q2 		$2.86M Hold
416,666
– – 0.04% 40
2024
Q1 		$5.89M Buy
+416,666
New +$6.34M 0.07% 46
2022
Q2 		– Sell
-695,000
Closed -$9.11M – 42
2022
Q1 		$9.11M Hold
695,000
– – 0.17% 40
2021
Q4 		$12.2M Hold
695,000
– – 0.21% 37
2021
Q3 		$15.1M Hold
695,000
– – 0.24% 41
2021
Q2 		$24.3M Sell
695,000
-105,000
-13% -$5.66M 0.42% 36
2021
Q1 		$78.9M Hold
800,000
– – 1.36% 16
2020
Q4 		$86.7M Hold
800,000
– – 1.49% 17
2020
Q3 		$82.4M Buy
800,000
+41,500
+5% +$6.21M 1.17% 19
2020
Q2 		$158M Buy
758,500
+43,500
+6% +$7.7M 3.13% 11
2020
Q1 		$69.9M Buy
715,000
+190,000
+36% +$22.2M 2.36% 15
2019
Q4 		$60.5M Buy
525,000
+100,000
+24% +$8.81M 1.78% 16
2019
Q3 		$23.2M Buy
425,000
+75,000
+21% +$8.45M 0.97% 22
2019
Q2 		$41.6M Buy
+350,000
New +$29M 1.44% 17

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Avoro Capital Advisors's ADVM Position: Q3 2024 in Review

Avoro Capital Advisors sold out of Adverum Biotechnologies (ADVM) in Q3 2024, closing a stake of 416,666 shares — an estimated $2.86M sold.

Avoro Capital Advisors first reported a position in ADVM in Q2 2019 and held it in 14 quarters. The position peaked at $158M in Q2 2020. 77 funds tracked by Wall St. Rank hold ADVM as of Q3 2024.

  • Avoro Capital Advisors reported no remaining Adverum Biotechnologies position as of Q3 2024 after selling out during the quarter.
  • Avoro Capital Advisors sold 416,666 Adverum Biotechnologies shares in Q3 2024, an estimated $2.86M.
  • Avoro Capital Advisors first reported a position in Adverum Biotechnologies in Q2 2019 and held it in 14 quarters.
  • Avoro Capital Advisors's Adverum Biotechnologies position peaked at $158M in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2024.

Based on Avoro Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.